Know Cancer

or
forgot password

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.


Phase 1
18 Years
N/A
Not Enrolling
Both
HIV Infections, Anus Neoplasms

Thank you

Trial Information

Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.


Patients with HIV infection have a significant risk of recurrence following local ablation
of intraepithelial neoplasia; thus, anogenital epithelial may become an increasingly
important cause of morbidity, and possibly mortality, as the HIV epidemic matures. Clinical
studies of non-HIV-infected subjects have established that synthetic retinoids inhibit the
progression of epithelial preneoplastic conditions and some neoplastic states.

In the Phase I portion of the study, 20 patients per site each receive isotretinoin in
escalating doses. If a patient experiences grade 2 or worse toxicity (or grade 3 or worse
hypertriglyceridemia), dose is reduced to the previously tolerated dose for the remainder of
the 6 week period. Patients are then reassessed for anal neoplasia; those with no
progression and no grade 2 or worse toxicity receive an additional 6 weeks of isotretinoin
in combination with interferon alfa-2a. For Phase II of the study, a separate group of
patients who have undergone ablative therapy are randomized to one of three arms (26
patients/arm): isotretinoin alone at the dose tolerated by at least 60 percent of patients
in Phase I; isotretinoin plus interferon alfa-2a; or observation only. Treatment continues
for 48 weeks.

Inclusion Criteria


Inclusion Criteria

Concurrent Medication:

Allowed:

- PCP prophylaxis (required for patients with CD4 count < 200 cells/mm3).

- Chemoprophylaxis for candidiasis and herpes simplex.

- Metronidazole for up to 14 days.

- Erythropoietin.

Patients must have:

- HIV seropositivity.

- NO active opportunistic infection requiring treatment with prohibited drugs.

- Phase I - Current grade 1 AIN (i.e., low grade SIL) OR treated or untreated grade 2
or 3 AIN (i.e., high grade SIL).

Phase II - Prior histologically confirmed grade 2 or 3 AIN / high grade SIL, with ablative
therapy within the past 30-90 days.

- Capability of complying with study protocol.

NOTE:

- The terms condyloma, grade 1 AIN, and low grade SIL are interchangeable. Grade 2 or 3
AIN is interchangeable with high grade SIL.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Active medical problems for which the patient is undergoing evaluations or for which
prohibited therapy is required.

- Other active malignancies requiring systemic therapy.

- Significant symptomatic cardiac disease.

NOTE:

- Patients with malignancies being managed with local therapy (e.g., Kaposi's sarcoma,
basal cell carcinoma) may enroll at the discretion of the site investigator.

Concurrent Medication:

Excluded:

- G-CSF (filgrastim).

- Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).

- Corticosteroids.

- Biologic response modifiers.

- Cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

- Radiation therapy.

Patients with the following prior conditions are excluded:

History of ventricular arrhythmias or myocardial infarction.

Prior Medication:

Excluded within 20 days prior to study entry:

- G-CSF (filgrastim).

- Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).

- Corticosteroids.

- Biologic response modifiers.

- Cytotoxic chemotherapy.

Prior Treatment:

Excluded within 20 days prior to study entry:

- Radiation therapy.

Excluded within 14 days prior to study entry:

- Transfusion.

Active substance abuse or illegal drug use (alcohol consumption is strongly discouraged).

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Primary Purpose: Treatment

Principal Investigator

Palefsky JM

Investigator Role:

Study Chair

Authority:

United States: Federal Government

Study ID:

ACTG 216

NCT ID:

NCT00000764

Start Date:

Completion Date:

July 1996

Related Keywords:

  • HIV Infections
  • Anus Neoplasms
  • Interferon Alfa-2a
  • Acquired Immunodeficiency Syndrome
  • AIDS-Related Complex
  • Anus Neoplasms
  • Papillomavirus, Human
  • Papovaviridae Infections
  • Tumor Virus Infections
  • Isotretinoin
  • HIV Infections
  • Acquired Immunodeficiency Syndrome
  • Anus Neoplasms
  • Neoplasms
  • Warts
  • Papillomavirus Infections

Name

Location

University of Washington AIDS CRSSeattle, Washington  98122